Antengene to Present Novel Cancer Therapy Platform at SITC Meeting
Antengene Corporation Limited announced it will present preclinical results of its novel Cos-TCE platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The presentation focuses on new technology for cancer treatment.
Shanghai and Hong Kong – Antengene Corporation Limited (SEHK: 6996.HK) announced that it will present the latest preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event is scheduled to take place from November 4th to 8th, 2026, in Phoenix, Arizona.
The presentation, delivered by Antengene's Chief Scientific Officer Dr. Bing Hou, will focus on the platform's preclinical outcomes in cancer therapy. The development aims to enhance T-cells' ability to identify and destroy cancer cells using more precise and effective mechanisms, intended to minimize side effects.
Antengene's Cos-TCE platform utilizes a new approach to T-cell activation in cancer treatment. The company has previously secured multiple drug approvals in various markets and has several promising drug candidates in its pipeline, targeting autoimmune diseases, solid tumors, and hematological malignancies.
The SITC meeting serves as a significant forum for immunotherapy research, and Antengene's presentation offers an opportunity to showcase advancements in cancer treatment development to the international scientific community. The company's objective is to continue developing innovative therapies to address significant unmet medical needs.